Philip Hemme, Author at Labiotech.eu

About

Young French-German Entrepreneur, Co-founder & CEO of Labiotech.eu. High-level table tennis player, and German beer/French Wine lover 🙂

Articles by Philip Hemme

News and Trends 27 Apr 2016

Interviewing the CEO who uses Probiotics as Needle-free Vaccines

This is my first interview from BioTrinity 2016 in London. I met with Tom Johnston, CEO of Mucosis, to learn more about the needle-free vaccine platform he is developing. Mucosis is a biotechnology company based in Gröningen, Netherlands (a city we covered here for its medtech innovation). It was founded in 2007 and has raised over €20M so […]

April 27, 2016 - 1 minutemin - By Philip Hemme

News and Trends 24 Apr 2016

What happened this week? Top 10 London Biotechs, CRISPR, AACR

1. Here are 10 Awesome London based Biotechs 2. ITW: This Biotech Startup wants to fix Youth Blindness with a Gene Therapy 3. These EU Biotechs presented groundbreaking results at World Biggest Cancer Meeting 4. New CRISPR Tool can cut RNA too: Gene Editing just got even Easier! 5. Who are France’s Young Innovators in […]

April 24, 2016 - 1 minutemin - By Philip Hemme

Gensight gene therapy biotech bernard gilly labiotech

News and Trends 18 Apr 2016

ITW: This Biotech Startup wants to fix Youth Blindness with a Gene Therapy

While on a stop in New York, I had a chance to chat with Bernard Gilly, the founder and CEO of the Paris biotech GenSight. I wanted to learn more about the company, which is one of the only examples in the World using Gene therapy to treat specific and rare types of blindness. GenSight […]

April 18, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 16 Apr 2016

What happened this week? 18 Top-VCs, CAR-T and CRISPR

1. 18 of the Best European VCs for Biotech in 2016 2. How CAR-T Cells Kill Cancer: Pictures start Moving 3. Meet the CEO who wants to transform Pretty Corals into therapies for Cancer 4. It’s World Parkinson’s Disease Day! #EndParkinsons 5. Modern Biotechnology is now 40 – Happy Birthday! From Inside Labiotech: Secret unveiled: CRISPR […]

April 16, 2016 - 1 minutemin - By Philip Hemme

labiotech thomas taapken epicolon biotech epigenomics cancer philipp hemme berlin

News and Trends 14 Apr 2016

We met the Biotech with the First & Only US Approved Blood Test for Colorectal Cancer

Colorectal cancer is the second biggest cancer killer in the US, but Epigenomics could dramatically improve this sad figure. A problem Berlin-based Epigenomics want to solve and just got a significant milestone: an FDA approval for commercialisation. I met with Thomas Taapken, the CEO of the company, in his office in Berlin, a nice historical building with 4 meters ceiling […]

April 14, 2016 - 6 minutesmins - By Philip Hemme

Europe VC top investors biotech life sciences finance

Best in Biotech 12 Apr 2016

18 of the Best European VCs for Biotech in 2016

As Genentech is celebrating its 40th Birthday, it is also the 40th birthday of Biotechnology and the 40th birthday of Biotech Venture Capitalists. These risk investors are deeply linked to any venture successes. And although Europe definitely has fewer than in the US, there’s still a significant amount of influence and wealth on this side […]

April 12, 2016 - 10 minutesmins - By Philip Hemme

News and Trends 6 Apr 2016

Interviewing the Swedish Biotech that started the first Phase II Trial in Bahrain

It’s the fist time I heard of a European Biotech company clinically co-operating with a country in the Arabic gulf… That’s why I was curious to interview Christina Herder, the CEO of the Stockholm-based Dilaforette, which launched a Phase II trial in co-operation with Bahrain and the rest of the Emirates. Dilaforette, as many Swedish […]

April 6, 2016 - 1 minutemin - By Philip Hemme

News and Trends 5 Apr 2016

Interviewing one of the Leading Biotech Investors in Scandinavia

The Karolinska Institute (Sweden) is worldwide famous for giving the Nobel Prize every year… It’s also home of Karolinska Development, an investment company span out from Karolinska Institute. I had the chance to meet with Viktor Drvota, its Chief Investment Officer at BIO-Europe Spring 2016 in Stockholm. We had a chance to talk about the […]

April 5, 2016 - 1 minutemin - By Philip Hemme

News and Trends 4 Apr 2016

Biotech Environment in 2016: Reverse Engineering the Ecosystem #BES2016

BIO-Europe Spring 2016 is starting off right away with the plenary opening session. The conference was about partnering, trends and opinion from both Biotechs and Pharma… This was the list of pretty impressive speakers: How are Big Pharma positioning themselves in 2016? J&J clearly wants to open up more to the outside of the organisation, […]

April 4, 2016 - 5 minutesmins - By Philip Hemme

News and Trends 3 Apr 2016

What happened this week? CRISPR Crew, SynBio Infograph, Novartis Venture Fund

1. Infographic: A Handy Guide to the European Synthetic Biology Startup Scene 2. Interviewing the Managing Director of the $750M Venture Fund of Novartis 3. The CRISPR ‘Crew’ continues World Tour of Scientific Prize Collection 4. UK Cannabis Drug in Phase III Trial Success for Rare Epilepsy 5. From Anti-Ageing Creams to Alzheimer’s, this Biotech ‘Milks’ Tropical Plants […]

April 3, 2016 - 1 minutemin - By Philip Hemme

philipp hemme labiotech conference novartis sachs biotech markus goebel

News and Trends 29 Mar 2016

Interviewing the Managing Director of the $750M Venture Fund of Novartis

This is last interview you will see from SACHS in Zurich. I met with Markus Goebel, the managing director of the Novartis Venture Fund. He almost played at home as he is living few dozen of kilometres outside the city in the lovely Swiss countryside. Novartis Venture Fund originates, as its name can tell, from […]

March 29, 2016 - 2 minutesmins - By Philip Hemme

hiv virus vaccine la provence retroviral biosahntech anrs

News and Trends 23 Mar 2016

No, this French Startup didn’t Discover the Cure for HIV…

This is the story of a French doctor and his start-ups which have been trying to develop a cure for HIV for the last 10 years. The problem resides in exaggerating, not publishing data…and then repeating this process again and again. Last week, the professor Erwann Loret and his start-up Biosantech did a press conference to announce new “breakthrough” […]

March 23, 2016 - 3 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us